News
The Augurex team brings together leading scientific, clinical, technical and commercial expertise to ensure that our research translates into advanced diagnostics for improved patient outcomes.
High 14-3-3η Amplifies the Risk of Rapid Radiographic Progression
In a study of over 800 rheumatoid arthritis (RA) patients, presented this week at the Canadian Rheumatology (CRA) Association Meeting, it was shown that a positive 14-3-3η blood test amplified the risk of rapid joint damage progression when added to current measures....
BC-Led Digital Technology Supercluster Awarded Federal Funding to Transform Canada’s Fastest-Growing Tech Sector
As a founding member, we are thrilled that the BC-led #DigitalSupercluster has been chosen. Truly an exciting day for technology innovation in Canada!
Canada’s Most Powerful Women: Top 100 Current Winners
Augurex CEO Norma Biln was awarded Canada's Most Powerful Women: Top 100 Award for her extraordinary leadership and continued drive to inspire others. The Top 100 Award Winner community now includes 1,005 remarkable women who together celebrate accomplishments, share...
Children get arthritis too; Data on a blood test to help characterize JIA and its subtypes.
At the world’s premier arthritis conference, the American College of Rheumatology Annual Meeting (ACR), taking place in San Diego on November 3rd-8th, leading investigators from the United States, Canada and Egypt will present new data on the 14-3-3η blood test....
USPTO Issues 14-3-3η Patent: Good News for RA Patients
NEWS RELEASE | OCTOBER 17, 2017 Vancouver, BC — Augurex Life Sciences Corp is proud to announce that 14-3-3η, a novel rheumatoid arthritis (RA) biomarker, is paving a future for better patient outcomes. Today the U.S Patent and Trademark Office (USPTO) has issued...
Explaining The “Why”; 14-3-3η’s Biological Role As A Basis For Its Clinical Utility
Vancouver, BC – June 13, 2017. At the annual European congress of rheumatology meeting, The European League Against Rheumatism (EULAR), taking place in Madrid, Spain on June 14-17, investigators present the continued understanding of 14-3-3η's role in rheumatoid...
Serial 14-3-3η testing: informing RA flare and joint damage risk as you treat-to-target
Vancouver, BC – April 18, 2017. At the premier Asia-Pacific rheumatology conference, the Japan College of Rheumatology Annual Scientific Meeting (JCR), taking place in Fukuoka, Japan on April 20-22, international investigators from the United States, Canada, and...
Accelerating the Transformation of Patient Care
Please see the Genome BC news release from last week. Augurex is proud of and appreciates the ongoing support that we receive from provincial and federal government programs to expedite JOINTstat™ access to patients worldwide. Augurex is recognized as an emerging...
14-3-3η: Informing the RA Continuum of Care
14-3-3η Informs the RA Continuum of Care Vancouver, BC – October 28, 2016. At the world’s premier rheumatology conference, the American College of Rheumatology Annual Meeting (ACR) in Washington, DC, November 11-16, international investigators from Sweden, the United...
New Testing And Treatment Improves Outlook For Those With Rheumatoid Arthritis
PREVENTION AND TREATMENT If you have been experiencing a prolonged period of pain, tenderness and stiffness around your joints, you should get to a doctor — and make it fast. Please read the full article on the personalhealthnews.ca website here...
JOINTstat™ – Transforming RA Patient Management
LifeLabs Medical Laboratory Services, the country's largest provider of community laboratory services, yesterday announced the Canadian launch of JOINTstat™ (14-3-3η), a biomarker blood test that is providing transformational insights into autoimmune joint damage...
LifeLabs Launches Arthritis Blood Test JOINTstat™ (14-3-3eta) in Canada
TORONTO, ONTARIO and VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 2, 2015) - LifeLabs Medical Laboratory Services ("LifeLabs") announced today the launch of JOINTstat™, a diagnostic blood test for rheumatoid arthritis. The JOINTstat™ blood test is the first test...
New Studies Expand the Large Body of Data on the Important Role of an Arthritis Protein; 14-3-3eta Blood Test
Vancouver, BC – November 5, 2014. Augurex Life Sciences Corp. announces a burgeoning body of data that further reveals the important role of a protein measured in blood, called 14-3-3eta, in rheumatoid arthritis (RA). Ten studies will be presented at the world's...
NRC and Augurex collaborate to improve treatments for rheumatoid arthritis
The National Research Council of Canada (NRC) and Augurex Life Sciences Corp. are proud to announce a collaborative agreement to develop new treatments for rheumatoid arthritis through personalized medicine. By combining their research and development expertise, NRC...
Arthritis Blood Test: 14-3-3eta Ground-Breaking Data
Vancouver, BC – May 29, 2014. Augurex Life Sciences Corp. announces a ground-breaking body of new data that will publish during the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology taking place June 11-14 in Paris. Investigators will present...
Rheumatoid Arthritis Blood Test (14-3-3eta) Data to be Presented at the World’s Premier Arthritis Conference
Vancouver, BC – October 25, 2013 - Augurex Life Sciences Corp. announced today the expansion of key data related to its innovative 14-3-3eta biomarkers with scheduled presentations next week at the prestigious American College of Rheumatology Annual Meeting, taking...
Blood Marker Can Help Diagnose Rheumatoid Arthritis; New Data at the 2012 Annual Meeting of the American College of Rheumatology
International arthritis investigators this week at the 2012 Annual Meeting of the American College of Rheumatology held in Washington, DC presented data related to the 14-3-3η protein and its auto-antibodies, a promising set of new blood-based markers from Augurex,...
Augurex Announces Exclusive License Agreement with Quest Diagnostics for the Development of Arthritis Biomarker 14-3-3η as a Testing Service in the U.S.
Augurex Life Sciences Corp. today announced that it has formed an exclusive license agreement with Quest Diagnostics, for the development of a clinical laboratory-developed testing service for the U.S. market, based on Augurex's rheumatoid arthritis (RA) 14-3-3η...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Home
Products
Science
About
News
Careers
Contact